Aflunov

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
II/0086	Extension of indication to include treatment of individuals 6 months of age and older for AFLUNOV, based on final results from study V87_30. This is a Phase 2, Randomized, Observer-Blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Several Doses of Antigen and MF59 Adjuvant Content	19/09/2024	21/10/2024	SmPC, Labelling and PL	Please refer to Scientific Discussion Aflunov-EMEA/H/C/002094/II/0086

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	in a Monovalent H5N1 Pandemic Influenza Vaccine in Healthy Pediatric Subjects 6 Months to < 9 Years of Age. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 5.4 of the RMP has also been approved. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement editorial changes to the product information including updating the SmPC in line with EMA guidance regarding sodium and potassium content. The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one				
PSUSA/10008 /202310	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)	16/05/2024	n/a		PRAC Recommendation - maintenance
II/0084/G	This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g.	20/07/2023	n/a		

	duplication of line) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process				

	of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information				
PSUSA/10008 /202210	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza	12/05/2023	n/a		PRAC Recommendation - maintenance

	vaccine (H5N1) (surface antigen, inactivated, adjuvanted)				
IB/0082	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	17/01/2023	n/a		
IB/0080	To update sections 4.4, 4.5 4.8 and 6.6 of the to increase clarity and harmonisation with the text approved in the Foclivia SmPC and with Seqirus seasonal vaccines (Fluad Tetra and Flucelvax Tetra). The labelling and package leaflet have been amended accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	30/09/2022	27/02/2023	SmPC, Annex II, Labelling and PL	To update sections 4.4, 4.5 4.8 and 6.6 of the to increase clarity and harmonisation with the text approved in the Foclivia SmPC and with Seqirus seasonal vaccines (Fluad Tetra and Flucelvax Tetra). The labelling and package leaflet have been amended accordingly.
WS/2341	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	29/09/2022	n/a		
WS/2248/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or	10/06/2022	n/a		

	starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
PSUSA/10008 /202110	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)	10/06/2022	n/a		PRAC Recommendation - maintenance
WS/2236/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol	02/06/2022	n/a		

WS/2151	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of the RMP (part I, II, III, IV, V and VI) for AFLUNOV and FOCLIVIA in order to align the list of safety concerns for the products. The modules 'Epidemiology of the indication and target population' and 'Identified and potential risks' and the section of missing information are updated. Some potential risks have been reclassified following the definition as per GVP Module V rev.2. RMP version 4.0 was approved with this variation. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	05/05/2022	n/a		
IA/0079	B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	20/04/2022	n/a		
WS/2226/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c - Change in the specification parameters	31/03/2022	27/02/2023	SmPC, Annex II and PL	

	and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
WS/2178/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for	09/12/2021	n/a		

	the AS -replacement or addition of a site where batch control/testing takes place				
WS/2152	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	18/11/2021	n/a		
WS/2167	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	11/11/2021	n/a		
IA/0070	A.7 - Administrative change - Deletion of manufacturing sites	04/08/2021	n/a		
WS/1985	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	01/07/2021	n/a		
PSUSA/10008 /202010	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza	10/06/2021	n/a		PRAC Recommendation - maintenance

	vaccine (H5N1) (surface antigen, inactivated, adjuvanted)				
IA/0069	A.7 - Administrative change - Deletion of manufacturing sites	23/02/2021	24/03/2022	Annex II and PL	
WS/1958/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	10/12/2020	n/a		
WS/1982	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.g.2 - Introduction of a post approval change management protocol related to the finished product	03/12/2020	n/a		
IA/0066/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or	06/11/2020	n/a		

	intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)				
IA/0064/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	20/10/2020	n/a		
WS/1796/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	03/09/2020	n/a		

WS/1860	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation	16/07/2020	n/a		
WS/1823/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	02/07/2020	n/a		
IA/0062	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	29/05/2020	n/a		

PSUSA/10008 /201910	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)	14/05/2020	n/a		PRAC Recommendation - maintenance
IB/0058	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	27/02/2020	n/a		
IB/0056	B.II.g.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol	17/01/2020	n/a		
IB/0055	B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product	09/12/2019	n/a		
IAIN/0054	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	22/10/2019	25/06/2020	Annex II and PL	
IAIN/0053	A.1 - Administrative change - Change in the name and/or address of the MAH	06/09/2019	25/06/2020	SmPC, Labelling and PL	
WS/1628	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	25/07/2019	n/a		

	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate				
WS/1600/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol	27/06/2019	25/06/2020	SmPC and PL	
II/0044/G	This was an application for a group of variations. Update of sections 2, 4.1, 4.4, 4.5, 4.6, 4.8 and 5.1 of the SmPC in order to update the immunogenicity and safety data based on final results from two phase III stratified, randomized, controlled, observer-blind, multicenter studies in adult and elderly subjects with comorbidity (study V87_25) or immunosuppressive conditions (study V87_26),	27/06/2019	25/06/2020	SmPC, Annex II, Labelling and PL	The MAH submitted final results from two studies included in the RMP that investigated immunogenicity and safety of two doses of Aflunov; 7.5 µg HA/dose) in adults and elderly (>61 years old) subjects with underlying medical conditions (study V87_25) or immunosuppressive conditions (study V87_26) compared to healthy individuals. The vaccine was immunogenic and safe in the population studied; however immune responses were low in elderly, immunocompromised and subjects with co-morbidities

	listed as post approval commitments in the RMP. Further data were also collected in the healthy adult and elderly populations used as comparison. The Package Leaflet and Labelling are updated accordingly. The updated RMP version 3.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the PI in light with the CHMP guideline on influenza vaccines and the SmPC guideline, and to make minor editorial corrections. The MAH took the opportunity to include editorial changes in Annex II to remove the manufacturers of the biological active substance GSK Vaccines, S.r.l. Via Fiorentina 1, 53100 Sienna, Italy and GSK Vaccines S.r.l. Bellaria - Rosia, 53018 Sovicille (Siena) Italy, following the outcome of procedure WS/xxxx/1145/G. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				compared to the immunogenicity profile in healthy adults. Antibody responses in patients with endogenous or iatrogenic immunosuppression may be insufficient to provide protection. In addition, some degree of cross-reactive immunity has been observed against H5N1 viruses of clades different to that of the vaccine strain. However, the degree of protection that may be elicited to H5N1 strains of other clades is unknown. Although the data suggest that the safety profile is similar in immunocompromised subject and subject with comorbidities to that observed in healthy subjects, some immunosuppressive conditions (tumors and transplant recipients) or comorbidities (especially vascular diseases and renal impairment) are scarcely represented. Consequently, such conditions are still considered missing information in the RMP. Therefore the use of the vaccine in subjects with such conditions should be strictly monitored and reported through PSUR.
PSUSA/10008 /201810	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)	16/05/2019	n/a		PRAC Recommendation - maintenance

IAIN/0052	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	10/05/2019	n/a		
WS/1562/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits	02/05/2019	n/a		
IB/0050/G	This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	25/04/2019	n/a		
WS/1530/G	This was an application for a group of variations following a worksharing procedure according to	28/03/2019	n/a		

	Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site				
WS/1538	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	13/12/2018	n/a		

	B.II.g.2 - Introduction of a post approval change management protocol related to the finished product				
WS/1368/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	21/06/2018	n/a		
PSUSA/10008 /201710	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)	17/05/2018	n/a		PRAC Recommendation - maintenance
WS/1311/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	08/03/2018	n/a		

	B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method				
WS/1323	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	01/02/2018	n/a		
WS/1214	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	19/10/2017	n/a		
WS/1165	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of	20/07/2017	n/a		

	the AS - Minor change in the manufacturing process of the AS				
WS/1143	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS	20/07/2017	n/a		
WS/1170	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	06/07/2017	n/a		
WS/1145/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal	15/06/2017	n/a		

	product and is not related to a protocol B.I.c.1.z - Change in immediate packaging of the AS - Other variation				
IA/0038/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised	01/06/2017	n/a		
IA/0037	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	19/05/2017		SmPC, Labelling and PL	
II/0032	B.II.b.3.e - Change in the manufacturing process of the finished or intermediate product - Introduction or increase in the overage that is used for the AS	18/05/2017	n/a		
PSUSA/10008 /201610	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)	05/05/2017	n/a		PRAC Recommendation - maintenance

II/0026/G	This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	15/12/2016	n/a		
IAIN/0030/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name	22/08/2016	n/a		

	and/or address of a manufacturer/importer responsible for batch release A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)				
IB/0029	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	02/08/2016	n/a		
IAIN/0028/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites	13/05/2016	16/08/2016	SmPC, Annex II, Labelling and PL	

PSUSA/10008 /201510	Periodic Safety Update EU Single assessment - pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)	13/05/2016	n/a		PRAC Recommendation - maintenance
IB/0025/G	This was an application for a group of variations. B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits	23/09/2015	n/a		
IAIN/0024	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	12/08/2015	16/08/2016	Annex II and PL	
R/0021	Renewal of the marketing authorisation.	21/05/2015	17/07/2015	SmPC, Annex II, Labelling and PL	Based on the review of available information, the CHMP is of the opinion that the quality, safety and efficacy of AFLUNOV continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The CHMP recommends that the renewal be granted with unlimited validity.
PSUSA/10008	Periodic Safety Update EU Single assessment -	21/05/2015	17/07/2015		Please refer to Aflunov PSUSA/00010008/201410 EPAR:

/201410	pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)				Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
T/0023	Marketing Authorisation Transfer from Novartis Vaccines and Diagnostics S.r.l to Novartis Vaccines Influenza S.r.l Transfer of Marketing Authorisation	05/05/2015	27/05/2015	SmPC, Labelling and PL	
IAIN/0022	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	30/04/2015	n/a		
IB/0020/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	22/04/2015	n/a		
II/0018/G	This was an application for a group of variations. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for	26/03/2015	n/a		

	sterile and non-frozen biological/immunological ASs B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.II.h.1.b.1 - Update to the Adventitious Agents Safety Evaluation information - Replacement of obsolete studies related to manufacturing steps and adventitious agents already reported in the dossier - with modifications of risk assessment B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product				
IB/0017/G	This was an application for a group of variations. B.I.c.1.z - Change in immediate packaging of the AS - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation A.7 - Administrative change - Deletion of manufacturing sites	01/09/2014	n/a		
PSUV/0014	Periodic Safety Update	08/05/2014	n/a		PRAC Recommendation - maintenance

IG/0426	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	11/04/2014	n/a		
IA/0015/G	This was an application for a group of variations. B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method	28/03/2014	n/a		
IB/0013	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	30/10/2013	18/12/2013	SmPC, Annex II, Labelling and PL	
II/0010	Change in immediate packaging of the adjuvant. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs	19/09/2013	n/a		
IA/0012/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS	15/08/2013	n/a		

	A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS				
IAIN/0009/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system	11/01/2013	n/a		
II/0005/G	This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.2.z - Changes in the manufacturing process of	13/12/2012	18/12/2013	Annex II	

	the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation				
II/0007/G	This was an application for a group of variations. Update of sections 4.3 and 4.4 of the SmPC in order to add a contraindication and a warning for cases of known hypersensitivity to barium sulphate, which has been added to the list of trace residues. In addition, section 4.8 of the SmPC was updated concerning the duration of adverse events based on post-marketing surveillance data and concerning severe cases of thrombocytopenia based on a cumulative review data. The Package Leaflet is updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data	15/11/2012	08/02/2013	SmPC and PL	Please refer to the scientific discussion of the Assessment Report Aflunov-H-2094-II-0007-G-AR.
IAIN/0008	C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same	28/09/2012	n/a		

	MAH				
IB/0006/G	This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure	20/06/2012	n/a		
II/0001	Change of virus used in manufacture from a A/VietNam/1194/2004 (H5N1) - like strain (NIBRG-14) to a A/turkey/Turkey/1/05 (H5N1) - like strain (NIBRG-23). B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza	15/03/2012	20/04/2012	SmPC, Labelling and PL	
II/0003	Update of the safety information in section 4.8 of the SmPC following CHMP request from FUM 004 based on data from study V87P1E1 on cross-reactivity after booster dose. In addition, the MAH took the opportunity to update sections 8 and 9 of the SmPC and Annex IIIA to include the Date of First Authorisation and the MA Numbers, and to make a minor editorial change in section 4.6. Furthermore the information on pediatric population in section 4.2 and 5.1 of the SmPC has been revised based on the	15/12/2011	06/02/2012	SmPC and Labelling	Section 4.8 of the SmPC was updated to reflect data from Study V87P1E1, which showed 72% of solicited reactions in adults and 39% in elderly. These numbers are higher than those detected after the previous doses, indicating a tendency towards an increased reactogenicity after a booster dose. Furthermore, in the elderly the reported reactions increased with the third booster dose when compared with the second dose.

	SmPC guideline. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH				
IAIN/0004	C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH	18/11/2011	n/a		
IA/0002/G	This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD C.I.9.f - Changes to an existing pharmacovigilance system as described in the DDPS - Deletion of topics covered by written procedure(s) describing	06/05/2011	n/a	Annex II	

	pharmacovigilance activities C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system				